Evidence map›Paper›PMID 32131556›Full record

ArticlePathogens (Basel, Switzerland)2020

Immune Phenotype and Functionality of

Lucy Mupfumi, Cheleka A M Mpande, Tim Reid, Sikhulile Moyo, Sanghyuk S Shin, Nicola Zetola, Tuelo Mogashoa, Rosemary M Musonda, Ishmael Kasvosve, Thomas J Scriba and 2 more

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Specific immune response toFrontiers in immunology · 2024
    Article
  3. Article
  4. Article
  5. The European respiratory journal · 2022
    Article
  6. Review
  7. Article
  8. Pathogens (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Lucy MupfumiDepartment of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Gaborone 4775, Botswana.
Cheleka A M MpandeSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7935, South Africa.
Tim ReidSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7935, South Africa.
Sikhulile MoyoBotswana Harvard AIDS Institute Partnership, Gaborone 320, Botswana.
Sanghyuk S ShinSue & Bill Gross School of Nursing, University of California Irvine, Irvine CA 92697, USA.
Nicola ZetolaInfectious Diseases Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA & Botswana-Upenn Partnership, Gaborone, Botswana.
Tuelo MogashoaDepartment of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Gaborone 4775, Botswana.
Rosemary M MusondaBotswana Harvard AIDS Institute Partnership, Gaborone 320, Botswana.
Ishmael KasvosveDepartment of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Gaborone 4775, Botswana.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7935, South Africa.
Elisa NemesSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town 7935, South Africa.
Simani GaseitsiweBotswana Harvard AIDS Institute Partnership, Gaborone 320, Botswana.
University of Cape Town · ZAHarvard University · USUniversity of Botswana · BWBotswana Open University · BWUniversity of California, Irvine · US

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
The Effect of Mixed-strain Mycobacterium tuberculosis Infections on TB Treatment Outcomes in Botswana: A Retrospective Cohort Study.K01AI118559 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHIN, SANGHYUK SAM · 2015 to 2019
$670k
Utility of Deep Sequencing for Detecting Heteroresistant Mycobacterium tuberculosis Infections among HIV-infected PersonsR21AI120838 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHIN, SANGHYUK SAM · 2015 to 2016
$418k
NIAID NIH HHS K01 AI118559NIAID NIH HHS R21 AI120838NIH HHS D43 TW010543NIH HHS K01AI118559sub-Saharan African Network for TB/HIV Research Excellence (SANTHE) Del-15-006
6 · The paper itself

Abstract

The performance of host blood-based biomarkers for tuberculosis (TB) in HIV-infected patients on antiretroviral therapy (ART) has not been fully assessed. We evaluated the immune phenotype and functionality of antigen-specific T-cell responses in HIV positive (+) participants with TB (n = 12) compared to HIV negative (-) participants with either TB (n = 9) or latent TB infection (LTBI) (n = 9). We show that the cytokine profile of Mtb-specific CD4+ T-cells in participants with TB, regardless of HIV status, was predominantly single IFN-γ or dual IFN-γ/ TNFα. Whilst ESAT-6/CFP-10 responding T-cells were predominantly of an effector memory (CD27-CD45RA-CCR7-) profile, HIV-specific T-cells were mainly of a central (CD27+CD45RA-CCR7+) and transitional memory (CD27+CD45RA+/-CCR7-) phenotype on both CD4+ and CD8+ T-cells. Using receiving operating characteristic (ROC) curve analysis, co-expression of CD38 and HLA-DR on ESAT-6/CFP-10 responding total cytokine-producing CD4+ T-cells had a high sensitivity for discriminating HIV+TB (100%, 95% CI 70-100) and HIV-TB (100%, 95% CI 70-100) from latent TB with high specificity (100%, 95% CI 68-100 for HIV-TB) at a cut-off value of 5% and 13%, respectively. TB treatment reduced the proportion of

Indexed as

CD38HLA-DRimmune activationtreatment response

Identifiers

PMID32131556
PMCPMC7157681
OpenAlexW3009294970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.